Newly listed stock has 27% upside potential! JM Financial issues buy call; Check target price and key triggers

JM Financial initiated coverage of Symbiotec Pharmalab with a Buy rating and a ₹1,622 target price, implying about 27% upside. It expects new capacity, CDMO and complex injectable growth to lift revenue, EBITDA and profit through FY29.
Read the full story on Mint Opens livemint.com in a new tab
Advertisement
OZYNIXCRM, HRMS & Business ToolsAI-powered business software — early access openContact us
This is a short summary of a story published by Mint, shown with a link to the original. The full story, photo and reporting belong to Mint.












